Current Approach To Chronic Hepatitis B Therapy

Year 2012, Volume: 14 Issue: 2, 75 - 78, 01.07.2012

Mehmet Faruk Geyik Ertuğrul Güçlü

Abstract

Chronic hepatitis B (CHB) is a serious infectious diseases, leading to life threateningcomplications such as liver cirrhosis, hepatic decompensation and hepatocelluler carcinoma.The main goal for treatment of CHB is to prevent these complications, and to reduce the viralload, because current antiviral therapies are inadequate to eradicate Hepatitis B virus infection.In this article, current state of antiviral therapy of CHB and antiviral drugs were summarized

Keywords

Chronic hepatitis B, Antiviral therapy, Pegylated interferon

Kronik Hepatit B Tedavisine Güncel Yaklaşım

Abstract

Kronik hepatit B (KHB) karaciğer sirozu, karaciğer yetmezliği ve hepatosellüler kanser gibihayatı tehdit eden komplikasyonlara neden olabilen ciddi bir enfeksiyon hastalığıdır. KHBtedavisinin ana hedefi bu komplikasyonların önlenmesi ve viral yükün azaltılmasıdır çünkümevcut antiviral tedaviler, Hepatit B virüs enfeksiyonunu tamamen temizlemekte yetersizdir.Bu makalede KHB’de uygulanan antiviral tedavinin güncel durumu ve antiviral ilaçlarözetlenmiştir

Keywords

Kronik hepatit B, Antiviral tedavi, Pegile interferon

References

• World Health Organization (WHO) Hepatitis B. http://www.who.int/mediacentre/factsheets/fs204/en/print.html (erişim: 19.06.2010).
• Alexander J, Kowdley KV. Epidemiology of Hepatitis B– Clinical Implications. MedGenMed. 2006;8(2):13.
• Zoulim F, Perrillo R. Hepatitis B. Reflections on the current approach to antiviral therapy. J Hepatol. 2008;48 Suppl 1:2- 19.
• EASL Clinical Practice Guidelines. Management of chronic hepatitis B. European Association for the Study of the Liver. J Hepatol. 2009;50(2):227-42.
• Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6(12):1315-41.
• Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2008;28(2):167-77.
• Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology. 2009;49(5 Suppl):4- 12.
• Lok AS, McMahon BJ. AASLD Practice Guidelines Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):1-36.
• Hepatit B infeksiyonunda tanı ve tedavi (Kronik hepatit B güncelleme toplantısı raporu). Viral Hepatitle Savaşım Derneği. Antalya 2008. http://www.vhsd.org/index_.htm (erişim: 20.09.2010).
• Kau A, Vermehren J, Sarrazin C Treatment predictors of a sustained virologic response in hepatitis B and CJ Hepatol. 2008;49(4):634-51.
• Demirtürk N. Yeni milenyumda kronik aktif hepatit-B tedavisi. T Klin Gastroenterohepatoloji. 2003;14:107-13.
• Pawlotsky JM. Hepatitis C virus resistance to antiviral therapy. Hepatology. 2000;32(5):889-96.
• Beşışık F. Kronik B hepatiti tedavisinde nukleozid analogları. İ, Tekeli E. Eds. Viral Hepatit 2007.Viral Hepatitle Savaşım Derneği. 2007:196-205
• Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess. 2006;10(28):1-183.
• Amarapurkar DN. Telbivudine: a new treatment for chronic hepatitis B. World J Gastroenterol. 2007;13(46):6150-5.
• Keeffe EB, Dieterich DT, Pawlotsky JM, Benhamou Y. Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol. 2008;6(3):268-74.
• Delaney WE, Borroto-Esoda K. Therapy of chronic hepatitis B: trends and developments. Curr Opin Pharmacol. 2008;8(5):532-40.
• Yuen MF, Lai CL. Treatment of chronic hepatitis B: Evolution over two decades. J Gastroenterol Hepatol. 2011;26 Suppl 1:138-43.
• Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43(9):595-612.